Details

Autor(en) / Beteiligte

• Seethapathy, Harish
• Lee, Meghan D
• Strohbehn, Ian A
• Efe, Orhan
• Rusibamayila, Nifasha
• Chute, Donald F
• Colvin, Robert B
• Rosales, Ivy A
• Fadden, Riley M
• Reynolds, Kerry L
• Sullivan, Ryan J
• Kaufman, Howard L
• Jhaveri, Kenar D
• Sise, Meghan E

Titel

Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib

Ist Teil von

• Nephrology, dialysis, transplantation, 2022-02, Vol.37 (3), p.507-514

Ort / Verlag

England: Oxford University Press

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Background Our objective was to characterize the incidence, risk factors and clinical features of acute kidney injury (AKI) in patients receiving dabrafenib and trametinib. Methods We performed a retrospective cohort study examining the kidney outcomes of patients in a large healthcare system who received dabrafenib/trametinib between 2010 and 2019. The primary outcome was AKI, defined as a 1.5-fold increase in serum creatinine from baseline within a 12-month study period. AKI severity and etiology was determined for each case by chart review. Logistic regression was used to evaluate baseline predictors of AKI. Results A total of 199 patients who received dabrafenib in our healthcare system from 2010 to 2019 were included in the analysis. Forty-two patients (21%) experienced AKI within 12 months; 10 patients (5% of the total cohort, 24% of AKI patients) experienced AKI occurring during a dabrafenib/trametinib-induced febrile syndrome characterized by fever, chills, gastrointestinal symptoms and elevated liver enzymes. Preexisting liver disease was the only significant predictor of AKI in the cohort. One patient had biopsy-proven granulomatous acute interstitial nephritis that resolved with corticosteroids. Conclusions Oncologists and nephrologists should be aware that AKI is common after dabrafenib/trametinib and a substantial number of cases occur in the setting of treatment-induced pyrexia.